S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
S&P 500   4,590.52 (+0.85%)
DOW   35,712.89 (+0.63%)
QQQ   383.17 (+0.83%)
AAPL   152.55 (+2.49%)
MSFT   322.34 (-0.26%)
FB   313.10 (+0.28%)
GOOGL   2,906.01 (-0.63%)
TSLA   1,068.74 (+2.98%)
AMZN   3,437.55 (+1.33%)
NVDA   247.40 (+1.18%)
BABA   169.43 (+0.12%)
NIO   39.75 (+1.12%)
CGC   13.11 (+2.58%)
GE   104.43 (+0.56%)
AMD   122.00 (-0.23%)
MU   69.78 (+2.26%)
T   25.53 (+1.88%)
F   16.86 (+8.70%)
ACB   6.99 (+2.19%)
DIS   170.04 (+0.29%)
PFE   43.34 (+0.86%)
BA   206.27 (-0.16%)
AMC   35.23 (+1.35%)
NASDAQ:DAWN

Day One Biopharmaceuticals Stock Forecast, Price & News

$23.17
+0.93 (+4.18 %)
(As of 10/28/2021 10:34 AM ET)
Add
Compare
Today's Range
$22.87
$23.17
50-Day Range
$20.55
$27.92
52-Week Range
$17.19
$28.70
Volume
23 shs
Average Volume
114,576 shs
Market Capitalization
$1.43 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive DAWN News and Ratings via Email

Sign-up to receive the latest news and ratings for Day One Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DAWN
Employees
20
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.43 billion
Next Earnings Date
11/9/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

903rd out of 1,372 stocks

Pharmaceutical Preparations Industry

442nd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Day One Biopharmaceuticals (NASDAQ:DAWN) Frequently Asked Questions

Is Day One Biopharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Day One Biopharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Day One Biopharmaceuticals stock.
View analyst ratings for Day One Biopharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Day One Biopharmaceuticals?

Wall Street analysts have given Day One Biopharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Day One Biopharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Day One Biopharmaceuticals' next earnings date?

Day One Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Day One Biopharmaceuticals
.

How were Day One Biopharmaceuticals' earnings last quarter?

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) released its earnings results on Monday, August, 9th. The company reported ($5.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.32) by $4.72.
View Day One Biopharmaceuticals' earnings history
.

What price target have analysts set for DAWN?

4 brokers have issued 1 year target prices for Day One Biopharmaceuticals' shares. Their forecasts range from $30.00 to $44.00. On average, they anticipate Day One Biopharmaceuticals' stock price to reach $37.33 in the next year. This suggests a possible upside of 61.1% from the stock's current price.
View analysts' price targets for Day One Biopharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Day One Biopharmaceuticals' key executives?

Day One Biopharmaceuticals' management team includes the following people:
  • Ms. Julie Papanek Grant M.B.A., Co-Founder & Chair of the Board (Age 39, Pay $62.91k)
  • Dr. Jeremy Bender M.B.A., Ph.D., CEO, Pres & Director (Age 49, Pay $481.36k)
  • Dr. Samuel C. Blackman M.D., Ph.D., Co-Founder & Chief Medical Officer (Age 52, Pay $477.1k)
  • Mr. Charles N. York II, COO, CFO & Sec. (Age 44)
  • Dr. Mike Preigh Ph.D., Chief of Technology Operations
  • Dr. Davy Chiodin Ph.D., Pharm.D., Chief Devel. Officer
  • Ms. Lisa Hamman Bowers, Chief Commercial Officer

When did Day One Biopharmaceuticals IPO?

(DAWN) raised $126 million in an initial public offering (IPO) on Thursday, May 27th 2021. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Day One Biopharmaceuticals' stock symbol?

Day One Biopharmaceuticals trades on the NASDAQ under the ticker symbol "DAWN."

When does Day One Biopharmaceuticals' lock-up period expire?

Day One Biopharmaceuticals' lock-up period expires on Tuesday, November 23rd. Day One Biopharmaceuticals had issued 10,000,000 shares in its public offering on May 27th. The total size of the offering was $160,000,000 based on an initial share price of $16.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Who are Day One Biopharmaceuticals' major shareholders?

Day One Biopharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Strs Ohio (0.00%). Company insiders that own Day One Biopharmaceuticals stock include Papanek Julie Grant and Venture Fund Xi LP Atlas.

Which major investors are buying Day One Biopharmaceuticals stock?

DAWN stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Day One Biopharmaceuticals stock in the last two years include Papanek Julie Grant, and Venture Fund Xi LP Atlas.

How do I buy shares of Day One Biopharmaceuticals?

Shares of DAWN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Day One Biopharmaceuticals' stock price today?

One share of DAWN stock can currently be purchased for approximately $23.17.

How much money does Day One Biopharmaceuticals make?

Day One Biopharmaceuticals has a market capitalization of $1.43 billion.

How many employees does Day One Biopharmaceuticals have?

Day One Biopharmaceuticals employs 20 workers across the globe.

What is Day One Biopharmaceuticals' official website?

The official website for Day One Biopharmaceuticals is dayonebio.com.

Where are Day One Biopharmaceuticals' headquarters?

Day One Biopharmaceuticals is headquartered at 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Day One Biopharmaceuticals?

Day One Biopharmaceuticals' mailing address is 395 OYSTER POINT BLVD STE 217, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-484-0899 or via email at [email protected].


This page was last updated on 10/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.